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Background
The Canadian HIV Vaccine Initiative (CHVI) is a five-year
initiative between the Government of Canada and the Bill
& Melinda Gates Foundation, and represents a significant
Canadian contribution to the Global HIV Vaccine Enter-
prise. The CHVI is part of Canada's long-term and com-
prehensive approach to addressing HIV/AIDS at home
and abroad, including the development of new preven-
tion technologies (NPTs). In support of this, the CHVI
explored the close relationship between HIV vaccines,
microbicides and pre-exposure prophylaxis (PrEP).
Methods
A discussion paper was commissioned to identify poten-
tial linkages and opportunities for collaborative efforts
among the three NPTs in the context of the CHVI's four
program areas: discovery and social research; clinical trial
capacity building and networks; pilot-scale manufactur-
ing facility for clinical trial lots; policy and regulatory
issues, and; community and social dimensions. Informa-
tion was gathered through document review of academic
and grey literature.
Results
There are many common issues/challenges to advancing
the development of new NPTs and significant opportuni-
ties for collaborative efforts among these NPT fields,
including sustainability of funding and clinical trial
capacity. The report also noted the importance of posi-
tioning HIV vaccines as part of an overall prevention strat-
egy, and that taking advantage of synergies between NPTs
could provide the best opportunity to advance the NPT
development agenda.
Conclusion
It is not known which technology will be available first or
the timelines for availability. However, it is increasingly
recognized by Canadian and global HIV stakeholders that
NPTs need to be part of a comprehensive HIV prevention
agenda to increase the chances of successfully responding
to the HIV/AIDS epidemic in the future. Canada has rec-
ognized the importance of including NPTs in a broad HIV
prevention framework currently in development.
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